Late and prolonged pseudoprogression in glioblastoma after treatment with lomustine and temozolomide

Journal of Clinical Oncology

Volumn 30, Issue 21, 2012, Pages

  Stuplich, Moritz ^a   Hadizadeh, Dariusch R ^a   Kuchelmeister, Klaus ^a   Scorzin, Jasmin ^a   Filss, Christian ^b   Langen, Karl Josef ^b   Schäfer, Niklas ^a   Mack, Frederic ^a   Schüller, Heinrich ^a   Simon, Matthias ^a   Glas, Martin ^a   Pietsch, Torsten ^a   Urbach, Horst ^a   Herrlinger, Ulrich ^a  

^a UNIVERSITY HOSPITAL BONN   (Germany)

^b German Institute of Neuroscience and Medicine   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

GADOLINIUM; LOMUSTINE; TEMOZOLOMIDE;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTRAST ENHANCEMENT; FEMALE; FOLLOW UP; GLIOBLASTOMA; HUMAN; MALE; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; TREATMENT OUTCOME; TREATMENT RESPONSE; TUMOR GROWTH;

ANTINEOPLASTIC AGENTS, ALKYLATING; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRAIN NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CONTRAST MEDIA; DACARBAZINE; DISEASE PROGRESSION; FATAL OUTCOME; FEMALE; GADOLINIUM; GLIOBLASTOMA; HUMANS; LOMUSTINE; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; RADIOTHERAPY, ADJUVANT; TREATMENT OUTCOME;

EID: 84864033781     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2011.40.9565     Document Type: Article

References (11)

1. Brandes AA, Franceschi E, Tosoni A, et al: MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients. J Clin Oncol 26:2192-2197, 2008
2. Brandsma D, Stalpers L, Taal W, et al: Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas. Lancet Oncol 9:453-461, 2008 (Pubitemid 351597795)
3. Hygino da Cruz LC Jr, Rodriguez I, Domingues RC, et al: Pseudoprogression and pseudoresponse: Imaging challenges in the assessment of posttreatment glioma. AJNR Am J Neuroradiol 32:1978-1985, 2011
4. Wen PY, Macdonald DR, Reardon DA, et al: Updated response assessment criteria for high-grade gliomas: Response Assessment in Neuro-Oncology Working Group. J Clin Oncol 28:1963-1972, 2010
5. Mikeska T, Bock C, El-Maarri O, et al: Optimization of quantitative MGMT promoter methylation analysis using pyrosequencing and combined bisulfite restriction analysis. J Mol Diagn 9:368-381, 2007 (Pubitemid 47305073)
6. Herrlinger U, Rieger J, Koch D, et al: Phase II trial of lomustine plus temozolomide chemotherapy in addition to radiotherapy in newly diagnosed glioblastoma: UKT-03. J Clin Oncol 24:4412-4417, 2006 (Pubitemid 46630979)
7. Glas M, Happold C, Rieger J, et al: Long-term survival of patients with glioblastoma treated with radiotherapy and lomustine plus temozolomide. J Clin Oncol 27:1257-1261, 2009
8. 18F]fluoroethyl)-l-tyrosine versus magnetic resonance imaging in the diagnosis of recurrent gliomas. Neurosurgery 57:505-511; discussion 505-511, 2005
9. Chaskis C, Neyns B, Michotte A, et al: Pseudoprogression after radiotherapy with concurrent temozolomide for high-grade glioma: Clinical observations and working recommendations. Surg Neurol 72:423-428, 2009
10. Chamberlain MC, Glantz MJ, Chalmers L, et al: Early necrosis following concurrent Temodar and radiotherapy in patients with glioblastoma. J Neurooncol 82:81-83, 2007
11. Peyre M, Cartalat-Carel S, Meyronet D, et al: Prolonged response without prolonged chemotherapy: A lesson from PCV chemotherapy in low-grade gliomas. Neuro Oncol 12:1078-1082, 2010